Industry News
Stay up-to-speed with our monthly round-up of the latest developments from across the industry.
If you would like to receive updates via our newsletter then please sign up here.
Haemostasis News Q1 2026
Our round-up of the latest developments from across the haemostasis industry for Q1 2026. REGULATORY FDA approved a new 2-gram presentation of Octapharma’s Fibryga (lyophilised human fibrinogen) for fibrinogen replacement in patients with acquired fibrinogen deficiency (AFD), building on its FDA approval in 2024 for a 1-gram presentation with nextaro reconstitution device (7 Jan) CLINICAL Metagenomi […]
Haemostasis Q4 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q4 2025. REGULATORY TAHO Pharma submitted the New Drug Application to the FDA for TAH3311 (apixaban oral dissolving film), developed on its proprietary Transepithelial Delivery System (1 Oct) ADLM (Association for Diagnostics & Laboratory Medicine) released new guidance on coagulation testing in patients […]
Haemostasis Q3 2025 News
Our round-up of the latest developments from across the haemostasis industry for Q3 2025. REGULATORY Novo Nordisk’s Alhemo (concizumab-mtci, a tissue factor pathway inhibitor antagonist) injection received positive opinion by the EMA CHMP, recommending label expansion to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors (25 Jul) Kedrion […]
